Samia Q. Khan, et al. EDIT-202, a Multiplexed CRISPR-Cas12a Gene-Edited iPSC-Derived NK Cell Therapy, has Prolonged Persistence, Promotes High Cytotoxicity, and Enhances In Vivo Tumor Killing. Presented at The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, May 16-19, 2022.